MARKET

QURE

QURE

Uniqure
NASDAQ
24.11
-0.60
-2.43%
Closed 19:38 02/11 EST
OPEN
24.71
PREV CLOSE
24.71
HIGH
24.71
LOW
23.41
VOLUME
1.30M
TURNOVER
0
52 WEEK HIGH
71.50
52 WEEK LOW
7.76
MARKET CAP
1.50B
P/E (TTM)
-5.4980
1D
5D
1M
3M
1Y
5Y
1D
Assessing uniQure (QURE) Valuation After New Securities Fraud Lawsuit On AMT-130 Disclosures
Simply Wall St · 15h ago
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
Barchart · 17h ago
INVESTOR ALERT: Securities Class Action Filed Against uniQURE N.V. – Investors Encouraged to Contact Kirby McInerney LLP
Barchart · 18h ago
Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Barchart · 22h ago
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Barchart · 1d ago
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit
Barchart · 1d ago
uniQure N.V. (QURE) Investors: Kessler Topaz Meltzer & Check, LLP Announces That the Firm Has Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. and Encourages Investors to Contact the Firm
Barchart · 1d ago
uniQure: Strengthening Gene Therapy Platform and Fabry Data Undervalued, Supporting Buy Rating and $70 Target
TipRanks · 2d ago
More
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Webull offers Uniqure NV stock information, including NASDAQ: QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.